O	0	11	Aflibercept	Aflibercept	NN	B-NP
O	12	13	(	(	(	O
O	13	20	AVE0005	AVE0005	NN	B-NP
O	20	21	)	)	)	O
O	21	22	:	:	:	O
O	23	25	an	an	DT	B-NP
O	26	37	alternative	alternative	JJ	I-NP
O	38	46	strategy	strategy	NN	I-NP
O	47	50	for	for	IN	B-PP
O	51	61	inhibiting	inhibit	VBG	B-VP
B-Cancer	62	68	tumour	tumour	NN	B-NP
O	69	81	angiogenesis	angiogenesis	NN	I-NP
O	82	84	by	by	IN	B-PP
O	85	93	vascular	vascular	JJ	B-NP
O	94	105	endothelial	endothelial	JJ	I-NP
O	106	112	growth	growth	NN	I-NP
O	113	120	factors	factor	NNS	I-NP
O	120	121	.	.	.	O

O	122	132	BACKGROUND	BACKGROUND	NN	B-NP
O	132	133	:	:	:	O
O	134	142	Aberrant	Aberrant	JJ	B-NP
O	143	155	angiogenesis	angiogenesis	NN	I-NP
O	156	158	is	be	VBZ	B-VP
O	159	160	a	a	DT	B-NP
O	161	169	landmark	landmark	NN	I-NP
O	170	177	feature	feature	NN	I-NP
O	178	180	in	in	IN	B-PP
B-Cancer	181	187	cancer	cancer	NN	B-NP
O	187	188	,	,	,	O
O	189	194	which	which	WDT	B-NP
O	195	197	is	be	VBZ	B-VP
O	198	207	important	important	JJ	B-ADJP
O	208	211	for	for	IN	B-PP
O	212	225	proliferation	proliferation	NN	B-NP
O	225	226	,	,	,	I-NP
O	227	233	growth	growth	NN	I-NP
O	234	237	and	and	CC	I-NP
O	238	248	metastasis	metastasis	NN	I-NP
O	248	249	,	,	,	O
O	250	253	and	and	CC	O
O	254	256	is	be	VBZ	B-VP
O	257	265	mediated	mediate	VBN	I-VP
O	266	268	by	by	IN	B-PP
O	269	276	various	various	JJ	B-NP
O	277	280	pro	pro	AFX	I-NP
O	280	281	-	-	HYPH	I-NP
O	281	291	angiogenic	angiogenic	JJ	I-NP
O	292	299	factors	factor	NNS	I-NP
O	299	300	.	.	.	O

O	301	304	The	The	DT	B-NP
O	305	309	VEGF	VEGF	NN	I-NP
O	310	317	pathway	pathway	NN	I-NP
O	318	320	is	be	VBZ	B-VP
O	321	324	one	one	CD	B-NP
O	325	327	of	of	IN	B-PP
O	328	331	the	the	DT	B-NP
O	332	336	most	most	RBS	I-NP
O	337	346	important	important	JJ	I-NP
O	347	350	and	and	CC	I-NP
O	351	355	best	good	JJS	I-NP
O	355	356	-	-	HYPH	I-NP
O	356	363	studied	study	VBN	I-NP
O	364	374	angiogenic	angiogenic	JJ	I-NP
O	375	383	pathways	pathway	NNS	I-NP
O	383	384	.	.	.	O

O	385	395	Inhibition	Inhibition	NN	B-NP
O	396	398	of	of	IN	B-PP
O	399	403	this	this	DT	B-NP
O	404	411	pathway	pathway	NN	I-NP
O	412	415	may	may	MD	B-VP
O	416	423	provide	provide	VB	I-VP
O	424	432	clinical	clinical	JJ	B-NP
O	433	441	benefits	benefit	NNS	I-NP
O	442	444	to	to	TO	B-PP
B-Cancer	445	451	cancer	cancer	NN	B-NP
O	452	460	patients	patient	NNS	I-NP
O	460	461	.	.	.	O

O	462	472	OBJECTIVES	OBJECTIVES	NNS	B-NP
O	472	473	:	:	:	O
O	474	484	Strategies	Strategy	NNS	B-NP
O	485	487	to	to	TO	B-VP
O	488	495	inhibit	inhibit	VB	I-VP
O	496	499	the	the	DT	B-NP
O	500	504	VEGF	VEGF	NN	I-NP
O	505	512	pathway	pathway	NN	I-NP
O	512	513	,	,	,	O
O	514	523	including	include	VBG	B-PP
O	524	534	antibodies	antibody	NNS	B-NP
O	535	537	to	to	TO	B-PP
O	538	542	VEGF	VEGF	NN	B-NP
O	542	543	,	,	,	O
O	544	554	antibodies	antibody	NNS	B-NP
O	555	557	to	to	TO	B-PP
O	558	561	the	the	DT	B-NP
B-Immaterial_anatomical_entity	562	575	extracellular	extracellular	JJ	I-NP
O	576	582	domain	domain	NN	I-NP
O	583	585	of	of	IN	B-PP
O	586	591	VEGFR	VEGFR	NN	B-NP
O	591	592	-	-	HYPH	B-NP
O	592	593	1	1	CD	I-NP
O	594	596	or	or	CC	I-NP
O	597	602	VEGFR	VEGFR	NN	I-NP
O	602	603	-	-	HYPH	O
O	603	604	2	2	CD	B-NP
O	604	605	,	,	,	O
O	606	611	decoy	decoy	NN	B-NP
O	612	621	receptors	receptor	NNS	I-NP
O	622	625	for	for	IN	B-PP
O	626	630	VEGF	VEGF	NN	B-NP
O	631	634	and	and	CC	I-NP
O	635	643	tyrosine	tyrosine	NN	I-NP
O	644	650	kinase	kinase	NN	I-NP
O	651	661	inhibitors	inhibitor	NNS	I-NP
O	662	664	of	of	IN	B-PP
O	665	671	VEGFRs	VEGFR	NNS	B-NP
O	671	672	,	,	,	O
O	673	676	are	be	VBP	B-VP
O	677	687	summarized	summarize	VBN	I-VP
O	687	688	.	.	.	O

O	689	696	METHODS	METHODS	NNS	B-NP
O	696	697	:	:	:	O
O	698	702	This	This	DT	B-NP
O	703	709	review	review	NN	I-NP
O	710	718	outlines	outline	VBZ	B-VP
O	719	722	and	and	CC	I-VP
O	723	731	compares	compare	VBZ	I-VP
O	732	735	the	the	DT	B-NP
O	736	742	latest	late	JJS	I-NP
O	743	754	development	development	NN	I-NP
O	755	757	of	of	IN	B-PP
O	758	763	these	these	DT	B-NP
O	764	774	strategies	strategy	NNS	I-NP
O	774	775	,	,	,	O
O	776	780	with	with	IN	B-PP
O	781	789	emphasis	emphasis	NN	B-NP
O	790	792	on	on	IN	B-PP
O	793	804	aflibercept	aflibercept	NN	B-NP
O	804	805	,	,	,	O
O	806	807	a	a	DT	B-NP
O	808	813	novel	novel	JJ	I-NP
O	814	819	decoy	decoy	NN	I-NP
O	820	826	fusion	fusion	NN	I-NP
O	827	834	protein	protein	NN	I-NP
O	835	837	of	of	IN	B-PP
O	838	844	domain	domain	NN	B-NP
O	845	846	2	2	CD	I-NP
O	847	849	of	of	IN	B-PP
O	850	855	VEGFR	VEGFR	NN	B-NP
O	855	856	-	-	HYPH	B-NP
O	856	857	1	1	CD	I-NP
O	858	861	and	and	CC	O
O	862	868	domain	domain	NN	B-NP
O	869	870	3	3	CD	I-NP
O	871	873	of	of	IN	B-PP
O	874	879	VEGFR	VEGFR	NN	B-NP
O	879	880	-	-	HYPH	O
O	880	881	2	2	CD	B-NP
O	882	886	with	with	IN	B-PP
O	887	890	the	the	DT	B-NP
O	891	893	Fc	Fc	NN	I-NP
O	894	902	fragment	fragment	NN	I-NP
O	903	905	of	of	IN	B-PP
O	906	910	IgG1	IgG1	NN	B-NP
O	910	911	.	.	.	O

O	912	919	RESULTS	RESULTS	NNS	B-NP
O	919	920	:	:	:	O
O	921	932	Aflibercept	Aflibercept	NN	B-NP
O	933	936	was	be	VBD	B-VP
O	937	942	shown	show	VBN	I-VP
O	943	945	to	to	TO	I-VP
O	946	950	have	have	VB	I-VP
O	951	956	early	early	JJ	B-NP
O	957	965	clinical	clinical	JJ	I-NP
O	966	974	activity	activity	NN	I-NP
O	974	975	.	.	.	O

O	976	984	Multiple	Multiple	JJ	B-NP
O	985	992	studies	study	NNS	I-NP
O	993	996	are	be	VBP	B-VP
O	997	1004	ongoing	ongoe	VBG	I-VP
O	1005	1007	to	to	TO	I-VP
O	1008	1017	determine	determine	VB	I-VP
O	1018	1021	the	the	DT	B-NP
O	1022	1030	clinical	clinical	JJ	I-NP
O	1031	1039	benefits	benefit	NNS	I-NP
O	1040	1042	of	of	IN	B-PP
O	1043	1054	aflibercept	aflibercept	NN	B-NP
O	1055	1057	in	in	IN	B-PP
B-Cancer	1058	1064	cancer	cancer	NN	B-NP
O	1065	1073	patients	patient	NNS	I-NP
O	1073	1074	.	.	.	O

